Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. Fava M, et al. Among authors: stankovic s. J Clin Psychiatry. 2019 Sep 24;80(6):19m12928. doi: 10.4088/JCP.19m12928. J Clin Psychiatry. 2019. PMID: 31556975 Free article. Clinical Trial.
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
Papakostas GI, Fava M, Freeman MP, Shelton RC, Thase ME, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S. Papakostas GI, et al. Among authors: stankovic s. Int Clin Psychopharmacol. 2020 Nov;35(6):313-321. doi: 10.1097/YIC.0000000000000328. Int Clin Psychopharmacol. 2020. PMID: 32804742 Free PMC article. Clinical Trial.
ENHANCE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin for Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment.
Bugarski-Kirola D, Bitter I, Liu IY, Abbs B, Stankovic S. Bugarski-Kirola D, et al. Among authors: stankovic s. Schizophr Bull Open. 2022 Jan 8;3(1):sgac006. doi: 10.1093/schizbullopen/sgac006. eCollection 2022 Jan. Schizophr Bull Open. 2022. PMID: 39144794 Free PMC article.
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S; ADP Investigators. Ballard C, et al. Among authors: stankovic s. Lancet Neurol. 2018 Mar;17(3):213-222. doi: 10.1016/S1474-4422(18)30039-5. Lancet Neurol. 2018. PMID: 29452684 Clinical Trial.
457 results